Poster Session II - A239 YOU ARE WHAT EATS YOU: EXPLORING MUCIN DEGRADATION BY THE IBD PATHOBIONT <i>CANDIDA ALBICANS</i>

Abstract Background Bacterial dysbiosis is well known to contribute to the pathophysiology of Crohn’s disease (CD), however, less is known about the gut mycobiome. The CD fungal pathobiont Candida albicans has been shown to be increased in abundance and associated with disease severity in patients with CD. There is emerging evidence that C. albicans can degrade gut mucins, an important part of the intestinal barrier, but whether this activity is a significant contributor to disease pathology and how the gut environment contributes to this phenotype is unknown. Specifically, the increased oxygen levels seen in the intestines of patients with CD may enhance C. albicans’ mucin degradation and its growth as a facultative anaerobe. Understanding how C. albicans reacts to the intestinal environment of patients with CD, in terms of its mucin degradation capability, could reveal mechanisms of pathophysiology and ultimately lead to novel treatments. Aims Determine the mucin degrading capability of C. albicans under both aerobic and anaerobic conditions. Methods Growth curves were conducted using commercially available type II and III porcine gastric mucins (PGM) and bovine submaxillary mucins (BSM) as nutrient sources. Mucin degradation was assessed using an agarose plate-based assay and gel electrophoresis with subsequent immunoblotting. Invasion into the agarose-mucin matrix was determined through cross-sectioning of the agarose and depth of invasion quantification using ImageJ. Intracellular uptake of mucins was visualized using fluorophore conjugated PGM and confocal microscopy. Assays were conducted under both aerobic and anaerobic conditions. Results C. albicans was able to grow on and degrade type II and III PGM but not BSM in the presence of an external carbon source (dextrose) suggesting mucins can only be utilized as a nitrogen source. Degradation was also assessed using gel electrophoresis and immunostaining for mucins showed the presence of degradation products. Furthermore, imaging fluorescently labeled PGM through confocal microscopy revealed significant intracellular fluorescence suggesting C. albicans can endocytose mucins. Growth, mucin degradation and invasion into the agarose-mucin matrix were reduced under anaerobic conditions. Conclusions C. albicans was able to degrade and internalize gastric mucins under aerobic conditions, indicating a potential role for increased gut oxygen in CD to exacerbate this phenotype. Utilization of gut mucins by C. albicans may potentially disrupt the mucus barrier in CD, further exacerbating disease. Funding Agencies CIHRWeston Family Foundation

Authors

Institutions

Publication Details

Journal
Journal of the Canadian Association of Gastroenterology
Published
2026-02-01
DOI
https://doi.org/10.1093/jcag/gwaf042.238
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Poster Session II - A239 YOU ARE WHAT EATS YOU: EXPLORING MUCIN DEGRADATION BY THE IBD PATHOBIONT CANDIDA ALBICANS

I Yavuukhulan, G R Lunken, B Vallance, J A Sousa
Journal of the Canadian Association of Gastroenterology
Inflammatory Bowel Disease
article

Poster Session II - A239 YOU ARE WHAT EATS YOU: EXPLORING MUCIN DEGRADATION BY THE IBD PATHOBIONT CANDIDA ALBICANS

I Yavuukhulan, G R Lunken, B Vallance, J A Sousa
article en

Abstract

Abstract Background Bacterial dysbiosis is well known to contribute to the pathophysiology of Crohn’s disease (CD), however, less is known about the gut mycobiome. The CD fungal pathobiont Candida albicans has been shown to be increased in abundance and associated with disease severity in patients with CD. There is emerging evidence that C. albicans can degrade gut mucins, an important part of the intestinal barrier, but whether this activity is a significant contributor to disease pathology and how the gut environment contributes to this phenotype is unknown. Specifically, the increased oxygen levels seen in the intestines of patients with CD may enhance C. albicans’ mucin degradation and its growth as a facultative anaerobe. Understanding how C. albicans reacts to the intestinal environment of patients with CD, in terms of its mucin degradation capability, could reveal mechanisms of pathophysiology and ultimately lead to novel treatments. Aims Determine the mucin degrading capability of C. albicans under both aerobic and anaerobic conditions. Methods Growth curves were conducted using commercially available type II and III porcine gastric mucins (PGM) and bovine submaxillary mucins (BSM) as nutrient sources. Mucin degradation was assessed using an agarose plate-based assay and gel electrophoresis with subsequent immunoblotting. Invasion into the agarose-mucin matrix was determined through cross-sectioning of the agarose and depth of invasion quantification using ImageJ. Intracellular uptake of mucins was visualized using fluorophore conjugated PGM and confocal microscopy. Assays were conducted under both aerobic and anaerobic conditions. Results C. albicans was able to grow on and degrade type II and III PGM but not BSM in the presence of an external carbon source (dextrose) suggesting mucins can only be utilized as a nitrogen source. Degradation was also assessed using gel electrophoresis and immunostaining for mucins showed the presence of degradation products. Furthermore, imaging fluorescently labeled PGM through confocal microscopy revealed significant intracellular fluorescence suggesting C. albicans can endocytose mucins. Growth, mucin degradation and invasion into the agarose-mucin matrix were reduced under anaerobic conditions. Conclusions C. albicans was able to degrade and internalize gastric mucins under aerobic conditions, indicating a potential role for increased gut oxygen in CD to exacerbate this phenotype. Utilization of gut mucins by C. albicans may potentially disrupt the mucus barrier in CD, further exacerbating disease. Funding Agencies CIHRWeston Family Foundation

Journal of the Canadian Association of GastroenterologyVol. 9(Supplement_1)
University of British Columbia (CA)
Openalex Percentile: Top 54%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.